Archives
-
MRSA Extracellular Vesicles Drive IL-8–Dependent OSCC Growth
2026-08-28
A 2026 Journal of Advanced Research study identifies extracellular vesicles from methicillin-resistant Staphylococcus aureus as active drivers of oral squamous cell carcinoma growth. The work links bacterial vesicle uptake to ERK/c-Jun activation, IL-8–CXCR1 signaling, CCL2 production, and JAK/STAT5A pathway activity, with genetic and pharmacological validation in cells and mice.
-
Epinephrine Bitartrate: Applied Research Workflows
2026-08-27
Build reproducible adrenergic assays with Epinephrine Bitartrate across cell, tissue, and translational models. This guide combines receptor-aware dosing, resource-efficient preparation, and practical troubleshooting for cardiovascular disease research and sympathetic nervous system studies.
-
PBA-Modified PAD4 Inhibitors Suppress Tumor NETs
2026-08-27
The 2023 European Journal of Medicinal Chemistry study developed phenylboronic acid-modified PAD4 inhibitors and identified Compound 5i as a tumor-targeted agent that suppresses the PAD4–H3cit–NET axis. Across sarcoma and breast cancer models, the compound reduced primary tumor growth and metastasis while showing favorable effects on the tumor immune microenvironment and systemic safety markers.
-
Part-Coated CEC for β2-Adrenergic Binding
2026-08-26
Liu and colleagues developed an open-tubular capillary electrochromatography method in which β2-adrenergic receptor was immobilized on only part of the capillary wall. Relating apparent electrophoretic mobility to coating length enabled binding-constant measurements from a single analyte concentration, reduced receptor consumption, and supported screening of both reference drugs and Radix Paeoniae Rubra extracts.
-
Allosteric PDK4 Inhibitors for Metabolic Disease
2026-08-26
This 2019 Journal of Medicinal Chemistry study describes anthraquinone-derived allosteric inhibitors of pyruvate dehydrogenase kinase 4, identifying compound 8c as a nanomolar biochemical inhibitor with metabolic and pharmacological promise. The work integrates medicinal chemistry, biochemical testing, pharmacokinetics, mouse efficacy models, cancer-related assays, and molecular docking to propose a new scaffold for PDK4-directed drug discovery.
-
Cytochalasin D for Actin Uptake Assays
2026-08-25
Use Cytochalasin D as a controlled cytoskeletal perturbation tool to test whether nanoparticle internalization depends on actin remodeling. This workflow connects corneal epithelial uptake, assay-quality controls, and carefully bounded extensions into cancer and antiviral research.
-
(5Z)-7-Oxozeaenol: TAK1 Signaling and Assays
2026-08-25
Explore how the TAK1 inhibitor (5Z)-7-Oxozeaenol can dissect inflammatory and metabolic-stress signaling. This guide translates recent AMPK–SQSTM1 research into practical assay strategies while defining the compound’s selectivity, limitations, and handling requirements.
-
Topotecan HCl Workflows for DNA Damage Research
2026-08-24
Build reproducible DNA-damage assays with Topotecan HCl, from short cytotoxicity screens to prolonged sphere-forming and xenograft-oriented studies. The workflow connects topoisomerase I-DNA complex stabilization with practical model selection, endpoint design, and troubleshooting across lung, breast, and prostate cancer systems.
-
Berberrubine, Metabolism, and Gut Microbiota in NAFLD
2026-08-24
Yang et al. show that berberrubine, a major berberine metabolite, improves diet-associated hepatic steatosis and insulin resistance in mice and oleic acid-treated HepG2 cells. The study links these effects to coordinated changes in glucose and lipid metabolic proteins and to remodeling of gut microbial communities, while also defining the limits of translating preclinical findings into clinical NAFLD therapy.
-
Z-VDVAD-FMK in Apoptosis Workflows
2026-08-23
Z-VDVAD-FMK enables targeted interrogation of caspase-2-centered apoptosis while helping researchers separate mitochondrial death signaling from caspase-independent and pyroptotic outcomes. This practical guide covers stock preparation, assay design, comparative readouts, and troubleshooting for cancer research and cell-death studies.
-
NP-40 Lysis Buffer for Neuroimmune Assays
2026-08-22
NP-40 Lysis Buffer supports native protein extraction when neuroimmune studies must connect cellular mechanism with reliable biochemical readouts. This article translates FPR2/ALX, microglial, NK-cell, and SYK-AKT findings into practical decisions for Western blotting, immunoprecipitation, and interaction-preserving assay design.
-
A 83-01 ALK-5 Inhibitor Workflow
2026-08-22
A 83-01 provides a practical way to test whether TGF-β/Smad activity drives fibroblast activation, EMT, or growth phenotypes. This workflow combines receptor-proximal pharmacology with single-cell-informed renal fibrosis assays, emphasizing dose design, controls, solubility, and interpretation limits.
-
Dicoumarol, IRE1α, and Tunicamycin-Induced Liver Injury
2026-08-21
A 2025 Life Sciences study combined molecular docking, an XBP1s reporter assay, cellular validation, and mouse models to identify dicoumarol as a candidate inhibitor of IRE1α signaling. The work shows how Tunicamycin- and carbon tetrachloride-induced ER stress can be used to test pathway-selective protection against acute liver injury.
-
MRE11 Lactylation Drives TNBC Radioresistance
2026-08-20
The reference study identifies lactate-dependent MRE11 Lys673 lactylation as a DNA-repair mechanism that protects triple-negative breast cancer cells from radiotherapy. It further shows that Saikosaponin D activates an HIF1α/HDAC5 pathway to reduce this modification, linking metabolic reprogramming to a potentially actionable radiosensitization strategy.
-
O-GlcNAcylation Rewires Wnt-Driven Bone Formation
2026-08-20
The reference study identifies O-GlcNAcylation as a required metabolic intermediary linking Wnt signaling to osteoblast differentiation, aerobic glycolysis, and bone formation. Its central mechanistic finding is that Wnt3a modifies PDK1 at Ser174, stabilizing PDK1 and redirecting glucose metabolism toward lactate production, with implications for fracture healing and anabolic osteoporosis research.